D.E. Shaw & Co
SGTX

D.E. Shaw & Co’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

D.E. Shaw & Co’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,189
Closed -$61K – 5960
2022
Q1 		$61K Sell
3,189
-368
-10% -$8.2K ﹤0.01% 5097
2021
Q4 		$128K Buy
+3,557
New +$202K ﹤0.01% 5008
2021
Q3 		– Sell
-1,111
Closed -$155K – 5381
2021
Q2 		$155K Buy
+1,111
New +$195K ﹤0.01% 4494

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's SGTX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 3,189 shares — an estimated $61K sold.

D.E. Shaw & Co first reported a position in SGTX in Q2 2021 and held it in 3 quarters. The position peaked at $155K in Q2 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 3,189 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $61K.
  • D.E. Shaw & Co first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Sigilon Therapeutics, Inc. Common Stock position peaked at $155K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.